Breast cancer treatment with sacituzumab and atropine
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether giving the drug sacituzumab govitecan together with atropine reduces side effects and improves tolerability in people with advanced breast cancer. You may be eligible if you have either triple-negative or hormone receptor-positive, HER2-negative breast cancer that hasn't responded to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and able to give informed consent
- You have advanced breast cancer that has spread (unresectable locally advanced or metastatic)
- You have not received more than two prior chemotherapy regimens for advanced disease
- You have adequate organ function (bone marrow, liver, kidneys)
- You are willing to provide tumor tissue and blood samples
- You agree to use effective contraception if applicable
- You have recovered from side effects of previous treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called sacituzumab govitecan (a type of antibody-drug conjugate that targets cancer cells) as the first treatment for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if it can help shrink or control the cancer.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
This trial tests different sequences of antibody-drug conjugates (a type of targeted chemotherapy) for people with ER-positive, HER2-low or ultra-low metastatic breast cancer that has stopped responding to hormone therapy and has progressed on Enhertu. You must have had 1–4 prior chemotherapies for metastatic disease.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted therapy) and Q901 (a study drug that blocks a protein needed for cancer cell growth)—in people with advanced triple-negative breast cancer who have already tried other treatments. The goal is to see if this combination can shrink or control the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.